U.S. FDA set to authorize COVID-19 vaccine boosters for immunocompromised patients - NBC News
Reuters
Published Aug 11, 2021 06:52PM ET
Updated Aug 11, 2021 09:02PM ET
(Reuters) - The U.S. Food and Drug Administration is expected to authorize a third booster dose of COVID-19 vaccines by Pfizer Inc (NYSE:PFE) and Moderna (NASDAQ:MRNA) Inc for people with weakened immune systems, NBC News reported on Wednesday.
The health agency will amend the emergency use authorizations for the two vaccines as soon as Thursday to allow immunocompromised people to get an additional dose, the report said, citing people familiar with the matter.
The agency is closely monitoring data as it becomes available from studies administering an additional dose of the authorized COVID-19 vaccines to immunocompromised individuals, FDA spokesperson Abby Capobianco said in a statement.
"The FDA, along with the CDC, is evaluating potential options on this issue, and will share information in the near future," Capobianco said.
A U.S. Centers for Disease Control and Prevention (CDC) advisory panel will meet on Friday to review data on booster doses in immune compromised individuals. While there is no vote listed on the draft agenda for the meeting, the Federal Register entry said a recommendation vote is scheduled.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.